LB Pharma Q1 net loss $19.1M; cash $365.6M; Phase 3 schizophrenia trial launched

LB PHARMACEUTICALS INC

2026-Q1 EPS reported -$0.67

Net loss of $19.1M in Q1 2026 vs $5.3M in Q1 2025; R&D expenses rose $11.2M to $14.6M.
Cash, equivalents, and marketable securities totaled $365.6M as of March 31, 2026; runway into Q2 2029.
Initiated pivotal Phase 3 NOVA-2 trial of LB-102 in acute schizophrenia; topline data H2 2027.
Phase 2 ILLUMINATE-1 trial in bipolar depression started Jan 2026; topline expected Q1 2028.
Completed $100M private placement in Feb 2026; Phase 2 in adjunctive MDD planned early 2027.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

LB PHARMACEUTICALS INC reported financial results for the first quarter ended on March 31, 2026.

Period: the first quarter ended on March 31, 2026
Result: reported results

Exact text from the filing

On May 12, 2026, LB Pharmaceuticals Inc (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

LB PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001193125-26-219529

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.